Online inquiry

IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9161MR)

This product GTTS-WQ9161MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9161MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2922MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ4531MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ6885MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ3700MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ9391MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ7677MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ4481MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ15429MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TSR-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW